Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).

Shailender Bhatia,Upendra Parvathaneni,Hailing Lu,Natalie Miller,Paul Ngheim,Jan Ter Meulen,David R Byrd,David M Koelle,Natalie Vandeven,Rima Kulikauskas,Michi Shinohara,Dafina Ibrani,Frank J Hsu

doi:10.1200/jco.2016.34.15_suppl.3021

Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).

Shailender Bhatia, Upendra Parvathaneni + Show 11 more

https://doi.org/10.1200/jco.2016.34.15_suppl.3021

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 12

Affiliation: Fred Hutch Cancer Center

#Expression Of Merkel Cell Polyomavirus #Merkel Cell Carcinoma + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

3021Background: MCC is an aggressive skin cancer with suboptimal therapies. Despite persistent expression of Merkel cell polyomavirus in ~80% of pts, MCC tumors are able to evade host immunity. G10...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.